1f92

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1f92" size="450" color="white" frame="true" align="right" spinBox="true" caption="1f92, resolution 2.6&Aring;" /> '''UROKINASE PLASMINOGE...)
Line 1: Line 1:
-
[[Image:1f92.gif|left|200px]]<br />
+
[[Image:1f92.gif|left|200px]]<br /><applet load="1f92" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1f92" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1f92, resolution 2.6&Aring;" />
caption="1f92, resolution 2.6&Aring;" />
'''UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX'''<br />
'''UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX'''<br />
==Overview==
==Overview==
-
Urokinase is a serine protease involved in cancer growth and metastasis., Here we present the first urokinase crystal structure in complex with, reversible inhibitors at 2.1 and 2.6 A resolution. These inhibitor complex, structures have been obtained from crystals of engineered urokinase type, plasminogen activator designed to obtain a crystal form open for inhibitor, soaking. The mutant C122S loses its flexible A-chain upon activation, cleavage and crystallizes in the presence of benzamidine, which was later, displaced by the desired inhibitor. This new soakable crystal form turned, out to be of great value in the process of structure-based drug design., The evaluated binding mode of amiloride, and UKI-1D revealed a new subsite, of the primary specificity pocket of urokinase that will be employed in, the future ligand optimisation process.
+
Urokinase is a serine protease involved in cancer growth and metastasis. Here we present the first urokinase crystal structure in complex with reversible inhibitors at 2.1 and 2.6 A resolution. These inhibitor complex structures have been obtained from crystals of engineered urokinase type plasminogen activator designed to obtain a crystal form open for inhibitor soaking. The mutant C122S loses its flexible A-chain upon activation cleavage and crystallizes in the presence of benzamidine, which was later displaced by the desired inhibitor. This new soakable crystal form turned out to be of great value in the process of structure-based drug design. The evaluated binding mode of amiloride, and UKI-1D revealed a new subsite of the primary specificity pocket of urokinase that will be employed in the future ligand optimisation process.
==Disease==
==Disease==
Line 11: Line 10:
==About this Structure==
==About this Structure==
-
1F92 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with SO4 and UKP as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1F92 OCA].
+
1F92 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=SO4:'>SO4</scene> and <scene name='pdbligand=UKP:'>UKP</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1F92 OCA].
==Reference==
==Reference==
Line 32: Line 31:
[[Category: urokinase]]
[[Category: urokinase]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 16:50:15 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:36:08 2008''

Revision as of 10:36, 21 February 2008


1f92, resolution 2.6Å

Drag the structure with the mouse to rotate

UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX

Contents

Overview

Urokinase is a serine protease involved in cancer growth and metastasis. Here we present the first urokinase crystal structure in complex with reversible inhibitors at 2.1 and 2.6 A resolution. These inhibitor complex structures have been obtained from crystals of engineered urokinase type plasminogen activator designed to obtain a crystal form open for inhibitor soaking. The mutant C122S loses its flexible A-chain upon activation cleavage and crystallizes in the presence of benzamidine, which was later displaced by the desired inhibitor. This new soakable crystal form turned out to be of great value in the process of structure-based drug design. The evaluated binding mode of amiloride, and UKI-1D revealed a new subsite of the primary specificity pocket of urokinase that will be employed in the future ligand optimisation process.

Disease

Known disease associated with this structure: Alzheimer disease, late-onset, susceptibility to OMIM:[191840]

About this Structure

1F92 is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as U-plasminogen activator, with EC number 3.4.21.73 Full crystallographic information is available from OCA.

Reference

Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design., Zeslawska E, Schweinitz A, Karcher A, Sondermann P, Sperl S, Sturzebecher J, Jacob U, J Mol Biol. 2000 Aug 11;301(2):465-75. PMID:10926521

Page seeded by OCA on Thu Feb 21 12:36:08 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools